Hot Clean Energy Stocks For 2018

In the market for people buying a cup of coffee outside their home, it’s essentially Starbucks (NASDAQ: SBUX) and everyone else.

While McDonald’s (NYSE: MCD) and Dunkin’ Brands’ (NASDAQ: DNKN) Dunkin’ Donuts both now sell premium espresso-based beverages along with other fancy coffee drinks, people don’t view those brands the way they see Starbucks. The Seattle-based coffee chain exists in its own world, where it can sell out of $10 cups of whisky-barrel-aged coffee while it opens more than a thousand Reserve stores selling pricier drinks than its normal, already expensive beverage lineup.

Dunkin’ Donuts and McDonald’s don’t have that kind of pricing ability because selling lattes and cappuccinos cannot change how consumers perceive their brands. Neither chain will ever be considered upscale no matter how many trendy items like cold brew they add. The companies do compete on price, but that isn’t likely to affect Starbucks.

Hot Clean Energy Stocks For 2018: Retail Properties of America, Inc.(RPAI)

Advisors’ Opinion:

  • [By Ant贸nio Costa]

    Retail Properties of America Inc (NYSE: RPAI) has been in an impressive rebound since the lows of August and the stock price action continues to become Bullish. However, RPAI has run into the downtrend line resistance again and this could lead to a brief period of sideways consolidation or price correction from current levels. On watch.

Hot Clean Energy Stocks For 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    Source:Micron Technology Inc Technical Charts by

    Valeant Pharmaceuticals Intl Inc (NASDAQ:VRX) stock facing resistance.

    Shares of specialty pharma company Valeant Pharmaceuticals Intl Inc (NYSE:VRX)are in a downtrend for more than two months now. Valeant Pharmaceuticals Intl Inc stock was down by almost 50% since its Q1 2017 earnings at the end of February. The stock had made a new 52-week low at $8.36 a week back. Since then the stock has been able to make a marginal recovery, gaining more than 10% this week. However, the stock is now facing resistance from its 20-day moving average. Valeant stock had been unable to break out above the resistance line in the past and had continued to slide downwards. The stock is again likely to face strong resistance from the 20-day moving average. The declining volumes over the week indicate that the stock will find it tough to make a bullish crossover, over the 20-day moving average.

  • [By Stark Merrifield]

    Bill Ackman: Fifty-year-old Ackmans career began in 1992 when he and fellow Harvard graduate David P. Berkowtiz founded the investment firm Gotham Partners. The firms high-profile bid for Rockefeller Center in New York caused investors to flock to the firm, growing it to $500 million in assets. Then in 2004, with $54 million in personal funding, Ackman started Pershing Square Capital Management. Through Pershing, Ackman bought significant shares in companies like Wendys Co. (Nasdaq: WEN), Target Corp. (NYSE: TGT), Chipotle Mexican Grill Inc. (NYSE: CMG), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). Today, Ackman is worth $1.4 billion and is No. 256 on the Forbes 400.

  • [By Lisa Levin] Related Chardan Analyst Suggests An AveXis-Ionis Pair Trade Why The Biogen-Ionis News Is A Boon For AveXis AveXis' (AVXS) CEO Sean Nolan on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related CLBS Earnings Scheduled For March 17, 2017 15 Biggest Mid-Day Gainers For Thursday Caladrius Biosciences beats by $0.07, beats on revenue (Seeking Alpha) Gainers
    Caladrius Biosciences Inc (NASDAQ: CLBS) shares rose 20.2 percent to $6.13 in pre-market trading after the company reported a narrower-than-expected quarterly loss.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 12.3 percent to $3.20 in pre-market trading after the company disclosed that it has licensed LNP delivery technology to Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for use in single messenger RNA product candidate.
    AveXis Inc (NASDAQ: AVXS) rose 12.2 percent to $81.66 in pre-market trading after the company reported topline data from Phase 1 trial of AVXS-101.
    TOP SHIPS Inc (NASDAQ: TOPS) shares rose 10.5 percent to $2.43 in pre-market trading after surging 109.52 percent on Thursday.
    ChipMOS TECHNOLOGIES INC. (NASDAQ: IMOS) rose 9.8 percent to $17.45 in pre-market trading after declining 0.44 percent on Thursday.
    Sino-Global Shipping America, Ltd. (NASDAQ: SINO) rose 8.3 percent to $3.38 in pre-market trading after climbing 23.81 percent on Thursday.
    Diana Containerships Inc (NASDAQ: DCIX) rose 7.6 percent to $2.99 in pre-market trading after surging 12.55 percent on Thursday.
    Steel Dynamics, Inc. (NASDAQ: STLD) rose 5.2 percent to $37.25 in pre-market trading. Steel Dynamics expects Q1 earnings of $0.77 to $0.81 per diluted share. The company also declared a quarterly cash dividend of $0.1550 per common share.
    Adobe Systems Incorporated (NASDAQ: ADBE)
  • [By Ben Levisohn]

    If it feels like it’s been all Valeant Pharmaceuticals International (VRX) today, I get it, and I promise this will be my last post on the company today. But really, how often do we get to see a fund manager acknowledge a spectacular mistake in such publicfashion?

    Photo: Andrew Harrer/Bloomberg

    As if it weren’t obvious yet, Ackman’s exit is bad news for the stock.Yes, some analysts have tried to focus on other issues that could be positive, but, really, as long as Ackman was around, you knew someone big had Valeant’s back. And now he’s gone. We at Barron’s were never too enthusiastic about Valeant–Vito Racanelliwrote bearishly on the company 2014–or Ackman’s involvement. But it he was your reason to be in Valeant, well consider what Wells Fargo analyst David Maris has to say:

    …we believe investors will take Pershing Squares exit as a reflection that 1) the outlook is negative; 2) the potential for meaningful near-term asset sales is unlikely; 3) the legal proceedings/investigations may have greater risk than the Street is appreciating; 4) a turnaround will take longer than expected or is not possible; and 5) the debtholders have an advantaged position in the capital structure, and as such the equity holders are at their mercy, especially in a bankruptcy situation. We believe investors would consider this as a sign that the next several years may not represent a major turnaround for the company.

    Shares of Valeant have dropped 11% to$10.76 at 3:12 p.m.

  • [By Ben Levisohn]

    Today is not a good day for Valeant Pharmaceuticals International (VRX). After an announcement last night that it was hiring a sales force to push Salix products suggested that the unit might not be sold, reports emerged that suggest that a Salix sale was not going to happen. And now letters from the SEC have emerged that question Valeant’s use of non-GAAP measures. Wells Fargo’s David Maris and team explain the significance:

    New SEC correspondence reveals potential problems with Valeant’s tax accounting and use of adjusted earnings metrics. In a series of letters made available by the SEC today, it appears the SEC has been questioning Valeant in regards to its tax reporting and disclosures, among other items. Recall that in our initiation of coverage report published in February 2016 we wrote extensively about potential problems arising from Valeant’s tax reporting, as well as its use of valuation allowances. It also appears from the correspondence that in response to concerns highlighted by the SEC, Valeant is re-assessing its current non-GAAP reporting and disclosures and is likely to present new measures and disclosures with its 2017 guidance and 4Q16 results, including a potential new adjusted net income measure. The correspondence between the SEC and Valeant can be found here: and here:

    In additional news we consider disappointing, the Wall Street Journal is reporting that Valeant’s rumored talks to sell its Salix business to Takeda have broken down over disagreement in price. Separately, following yesterday’s market close, Valeant issued a press release announcing its initiation of a primary care salesforce for its Xifaxan and Relistor products. Valeant stated that the associated cost would not impact 2016 guidance; however, there was no indication of the potential impact to 2017.

    Shares of Valeant Pharmaceuticals International have dropped 9% to $15.61 at

  • [By Kumar Abhishek] Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is sprouting some green shoots. But Valeant stock remains a risky bet.

    Despite posting strong results, the troubles for Canada based specialty pharma company Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is far from over. In the last two trading sessions, shares of Canada basedtroubled drug makerhave lost over 7% after the company came out with a plan to raise more than $750 million in debt in a private offeringof 5.5% notes due in 2025. Valeant will use a part of the proceeds to pay down term loans due in 2022.

Hot Clean Energy Stocks For 2018: CytRx Corporation(CYTR)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.

    If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.

    Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.

    Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.


Advisors’ Opinion:

  • [By Jim Robertson]

    Small cap Florida insurance stock Universal Insurance Holdings (NYSE: UVE) has taken a hit with shares downalmost 17%over the past week on predictions that Hurricane Irma would hit Florida albeit sharesrose 8.51%on Friday when it became clear that it would not be as catastrophic as feared:

Leave a Reply

Your email address will not be published. Required fields are marked *